Journal profile · Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Acta Pharmaceutica Sinica B
ISSN 2211-3835 · eISSN 2211-3843 · Elsevier BV · CHINA MAINLAND · Monthly · Founded 2011
Acta Pharmaceutica Sinica B: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 14.49; fully open access; APC about USD 2,600; median 142 days to acceptance (131 articles, last 24 months); community-reported acceptance: 9%; 501 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Acta Pharmaceutica Sinica B is published by Elsevier BV and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Nanoplatforms for cancer theranostics, Nanoparticle-Based Drug Delivery and RNA Interference and Gene Delivery, together about 26% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.APSB is the Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, peer reviewed under the responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical AssociationAPSB is a series of journal of Acta Pharmaceutica Sinica, which was founded in 1953, indexed in Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, Current Bibliography on Science and Technology, etc. It is sponsored by Insititute of Materia Medica, Chineses Acedemy of Medical Sciences and Chinese Pharmaceutical Association, production and hosting by Elsevier B.V.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Editor-in-chief Jiandong JiangPublisher website
Editorial board by country: 76 in mainland China (about 52%); most named Mainland China 76, United States 49, United Kingdom 3, Italy 3, South Korea 2 (146 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoplatforms for cancer theranosticsEngineering12%
- Nanoparticle-Based Drug DeliveryMaterials Science7.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology6.5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5%
- Ferroelectric and Negative Capacitance DevicesEngineering4.3%
- Big Data and Digital EconomyComputer Science4.3%
- Computational Drug Discovery MethodsComputer Science3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
CASPublisher website
Other: Index Medicus
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.49LetPub ·
- Impact factor (publisher)
- 14.6Publisher website ·
- CiteScore 2026-06
- 24.4LetPub ·
- CiteScore (publisher)
- 24.4Publisher website ·
- SJR 2026-06
- 3.44LetPub ·
- SNIP 2026-06
- 2.52LetPub ·
- h-index
- 28LetPub ·
- h-index
- 168OpenAlex ·
- i10-index
- 2,005OpenAlex ·
- 2-year mean citedness
- 10.22OpenAlex ·
- Self-citation rate
- 4.1%LetPub ·
- Share of gold OA articles
- 99.37%LetPub ·
Volume
- Articles per year
- 345LetPub ·
Articles by year OpenAlex count · 3,272 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 375 | 375 | 232 |
| 2025 | 501 | 501 | 4,026 |
| 2024 | 356 | 356 | 8,336 |
| 2023 | 311 | 311 | 10,634 |
| 2022 | 319 | 319 | 16,946 |
| 2021 | 352 | 352 | 28,401 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
142 daysMedian, submission to acceptance · P25–P75 95 days – 198 days
- Acceptance to online
- median 69 days (131 articles)
- Submission to online
- median 227 days
- Sample
- 131 articles with submission and acceptance dates (825 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 19 weeksLetPub ·
- Average acceptance (community reports)
- 9%LetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 38 daysPublisher website ·
- Submission to acceptance
- 210 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Submission to publication (journal-reported)
- about 44 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,600 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,600 / EUR 2,430 / GBP 2,080 / JPY 322,480 | — | — | |
| LetPub | USD 2,600 / USD 2,000 | Yes | — | |
| Publisher website | USD 2,600 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 1
- Reference style
- Numbered, in order of citation
- Graphical abstract
- Optional
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Double anonymized peer review Model summary
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- CHINA MAINLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2011
- ISSN
- 2211-3835
- Electronic ISSN
- 2211-3843
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about Acta Pharmaceutica Sinica B
What CAS zone is Acta Pharmaceutica Sinica B in?
In the 2025 upgraded edition of the CAS Journal Ranking, Acta Pharmaceutica Sinica B is in Zone 1 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Acta Pharmaceutica Sinica B?
The latest impact factor listed by LetPub is 14.49; CiteScore 24.4, h-index 168.
How long does peer review take at Acta Pharmaceutica Sinica B?
Based on the dates recorded on 131 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 142 days (interquartile range 95–198 days); authors report an average review time of about 19 weeks; the community-reported acceptance is “9%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Acta Pharmaceutica Sinica B?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 1; Reference style: Numbered, in order of citation; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Acta Pharmaceutica Sinica B based?
Of the 146 board members whose country the journal's board page names, 76 (about 52%) are in mainland China; the countries named most often are Mainland China (76), United States (49) and United Kingdom (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Acta Pharmaceutica Sinica B?
According to LetPub and DOAJ records, Acta Pharmaceutica Sinica B is indexed in SCIE, Scopus and DOAJ. The journal's website also lists CAS; that list has not been checked against each database.
Is Acta Pharmaceutica Sinica B open access, and what is the APC?
Acta Pharmaceutica Sinica B is a fully open-access journal. APC about USD 2,600.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .